Laura J. van ‘t Veer, PhD

University of Amersterdam, Faculty of Mathematics and Natural Sciences, B.Sc and M.Sc, 1976-1984, Biology, Molecular Oncology
University of Leiden, Leiden University Medical Center, Dept. of Clinical Oncology, PhD, 1984-1989, Oncogene Activation and Tumorigenesis

• 1993-present
  Molecular Biologist, Clinical Molecular Geneticist, Group Leader Molecular Pathology, Dept. of Pathology and Division of Experimental Therapy, The Netherlands Cancer Institute
• 1995-2005
  Head DNA-diagnostic Laboratory of the Family Cancer Clinic, The Netherlands Cancer Institute
• 1997-2003
  Head Family Cancer Clinic, The Netherlands Cancer Institute
• 2002-2010
  Honorary staff member, Department of Surgery, Leiden University Medical Center, The Netherlands
• 2004-2007
  Chief Operating Officer, Agendia BV, Amsterdam (part-time)
• 2007
  Chief Research Officer, Agendia BV, Amsterdam (part-time)
• 2007-2010
  Head Division Diagnostic Oncology (ad interim; includes Dept's Pathology, Radiology, Nuclear Medicine, Clinical Chemistry, Family Cancer Clinic), The Netherlands Cancer Institute
• 2008-2009
  Sabbatical Leave (1 yr), UCSF Comprehensive Cancer Center and Lawrence Berkeley National Laboratories - Life Sciences, San Francisco/Berkeley, USA
• 2010-present
  Professor, Laboratory Medicine, University of California, San Francisco
• 2011-present
  Angela and Shu Kai Chan Endowed Chair in Cancer Research, Department of Laboratory Medicine, University of California, San Francisco

• 2005
  IARC Medal of Honor, Lyon, France
• 2006
  Van der Scheuren award lecture for European Breast Cancer Research, EBCC5
• 2007
  ESMO Lifetime Achievement Award for Translational Research in Breast Cancer
• 2007, 2008
  Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award
• 2009
  First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine

• Van 't Veer LJ*, Dai H*, Van de Vijver MJ*, He YD, Hart AAM, Mao M, Peterse JL, Van der Kooij K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling of breast cancer predicts clinical outcome of disease. Nature 2002; 615, 530-536. PMID: 11823860
• Van de Vijver MJ*, He YD*, Van ' t Veer LJ*, Dai H, Hart AAM, Voskuil D, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Van der Velde T, Bartelink H, Rodenhuis S, Rutgers ETh, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002; 347, 1999-2009. * as equal first authors PMID: 12490681
• Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, Van 't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. New Engl J Med. 2006; 355: 560-9. PMID: 16899776
• Buyse M, Loi S, Van 't Veer LJ, Viale G, Delorenzi M, Glas A, Saghatchian d’Assignies M, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart M, on behalf of the TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 17: 1183-92. PMID: 16954471
• Schmidt MK, Tollenaar RAEM, De Kemp S, Broeks A, Cornelisse CJ, Smit VTHBM, Peterse JL, Van Leeuwen FE, Van 't Veer LJ. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007; 25: 64-9. PMID: 17132695
• Van 't Veer, L.J., Bernards R. Insight Review: Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452, 564-570. PMID: 18385730
• Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van 't Veer LJ, On behalf of the TRANSBIG consortium. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2008; Jul 27 Epub. PMID: 18661261
• Straver ME, Glas AM, Hanneman J, Wesseling J, Van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, Van Tinteren H, Van 't Veer LJ, Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; Feb 13 Epub. PMID: 19214742
• Mook S, Bonnefoi H, Pruneri G, Larismont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van 't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling: logistics pilot study preceding the MINDACT trial. Eur J Cancer 2009; 45: 1201-18. PMID: 19232484
• Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding. Schmidt MK, Vermeulen E, Tollenaar RA, Van't Veer LJ, van Leeuwen FE. Eur J Cancer. 2009 Sep;45(13):2376-82. PMID: 19362816
• Gaudet MM, Milne RL, Cox A, 51 others, Broeks A, Schmidt MK, Van Leeuwen FE, Van 't Veer LJ, 55 others, Pharoah PD, Easton DF, Garcia-Closas M, Breast Cancer Association Consortium Five polymorphisms and breast cancer risk: results from the breast Cancer Association Consortium. Cancer Epid Biom Prev 2009; 18: 1610-6. PMCID: PMC2737177
• Albain KS, Paik S, Van 't Veer LJ. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene arrays. The Breast 18, 2009, Oct;18 Suppl 3:S141-5. PMID: 19914534
• Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, Van't Veer LJ, Ravdin PM. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009 Nov;10(11):1070-6. PMID: 19801202
• He Y, Van 't Veer LJ, Mikolajewska-Hanclich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID, van de Velde CJ, Marijnen CA. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009 Nov 15;15(22):6956-62. PMID: 19903786
• Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, Van 't Veer LJ. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010 Apr;120(3):655-61. PMID: 20204499